➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Moodys
Boehringer Ingelheim
Dow
Baxter

Last Updated: July 13, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Psilocybin


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Psilocybin?

Psilocybin is an investigational drug.

There have been 45 clinical trials for Psilocybin. The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2017.

The most common disease conditions in clinical trials are Depression, Depressive Disorder, and Disease. The leading clinical trial sponsors are Heffter Research Institute, Johns Hopkins University, and Yale University.

There are six hundred and twenty-one US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Psilocybin
TitleSponsorPhase
Clinical and Mechanistic Effects of Psilocybin in Alcohol Addicted PatientsSchweizerischer NationalfondsPhase 2
Clinical and Mechanistic Effects of Psilocybin in Alcohol Addicted PatientsUniversity of ZurichPhase 2
Effects of Dimethyltryptamine in Healthy SubjectsMatthias LiechtiPhase 1

See all Psilocybin clinical trials

Clinical Trial Summary for Psilocybin

Top disease conditions for Psilocybin
Top clinical trial sponsors for Psilocybin

See all Psilocybin clinical trials

US Patents for Psilocybin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Psilocybin   Start Trial Devices and methods for continuous analyte monitoring DexCom, Inc. (San Diego, CA)   Start Trial
Psilocybin   Start Trial Devices and methods for continuous analyte monitoring DexCom, Inc. (San Diego, CA)   Start Trial
Psilocybin   Start Trial Indicator and analytics for sensor insertion in a continuous analyte monitoring system and related methods DexCom, Inc. (San Diego, CA)   Start Trial
Psilocybin   Start Trial Advanced analyte sensor calibration and error detection DexCom, Inc. (San Diego, CA)   Start Trial
Psilocybin   Start Trial Drug device configured for wireless communication Pop Test Abuse Deterrent Technology, LLC (Cliffside Park, NJ)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Psilocybin

Drugname Country Document Number Estimated Expiration Related US Patent
Psilocybin European Patent Office 3069279 2033-11-14   Start Trial
Psilocybin World Intellectual Property Organization (WIPO) 2015073459 2033-11-14   Start Trial
Psilocybin European Patent Office 3069279 2033-11-14   Start Trial
Psilocybin World Intellectual Property Organization (WIPO) 2015073459 2033-11-14   Start Trial
Psilocybin European Patent Office 3068302 2033-11-14   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Boehringer Ingelheim
Merck
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.